Raymond James reiterates Market Perform on Bristol-Myers stock By Investing.com

Raymond James cut Bristol-Myers Squibb’s Q1 2026 EPS estimate to $1.49 from $1.59 and trimmed full-year 2026 EPS to $6.28 from $6.32, while keeping a Market Perform rating. The revised estimates remain slightly above consensus at $1.43 for Q1 and $6.27 for FY2026, with the company set to report before the April 30, 2026 open. Shares are up 36% over the past six months, and the article also highlights a 4.34% dividend yield and multiple clinical/program updates.

Analysis

The setup is less about the quarter and more about the bar management into the second half: BMY’s near-term estimates are drifting modestly higher relative to consensus, but the market is already discounting a lot of that stability after a strong multi-month rerating. That leaves the stock vulnerable to a classic “good enough, but not better” reaction: if management merely reaffirms full-year guidance and doesn’t show accelerating U.S. oncology demand or cleaner expense leverage, the tape can fade even on an in-line print.

The bigger second-order issue is capital allocation quality versus pipeline optionality. A 4%+ dividend yield helps support the name, but it also signals a market that is paying for yield and defending cash flows while waiting for a credible growth inflection; if that inflection slips into 2027, the stock likely compresses from a cash-yield story back to a low-growth pharma multiple. Conversely, any evidence that operating expenses are peaking while Camzyos/Eliquis durability offsets Revlimid erosion would force a re-rating because the market is currently underpricing the convexity of a cleaner earnings revision cycle.

Consensus appears to be anchoring on “stable defensive compounder,” but the more interesting asymmetry is that downside from here is mostly estimate reset risk, while upside requires multiple expansion driven by pipeline read-throughs. That makes this a catalyst-driven name, not a momentum name: the next 2-4 weeks are about earnings reaction, but the real move depends on whether second-half Phase 3 updates reduce perceived patent/pipeline gap risk. If those data disappoint, the stock can give back a meaningful portion of the recent gain even if FY26 numbers hold.

Key Decisions for Investors

• Hold a tactical long only into the April 30 print, then trim 50-75% on any gap-up above the recent range; risk/reward favors selling strength because the near-term estimate revision is already in the price.
• If you want to stay exposed, structure a BMY call spread for the next 6-9 months rather than stock: upside is tied to second-half 2026 catalyst delivery, while defined risk limits drawdown if the quarter is merely in line.
• Pair trade: long BMY / short a higher-multiple large-cap pharma with more stretched expectations over the next 1-2 quarters; BMY’s yield and defensive cash flow make it the cleaner “quality with a catalyst” leg if sentiment remains cautious.
• Buy the post-earnings dip only if management confirms FY26 expense discipline and no deterioration in U.S. prescription trends; if either slips, the name likely de-rates back toward mid-teens earnings multiple.
• Do not chase the stock pre-earnings after the 6-month rally; best entry is a 3-5% pullback or a confirmed post-print continuation only if guidance language tightens and Phase 3 timing remains intact.